1. Inicio
  2. Proyectos y Estudios
  3. a phase IIa, randomized, double-blind, placebo-controlled, multiple dose, multicenter, parallel-group study to investigate the safety, tolerability, and the effect of ro7269162 on amyloid and non-amyloid disease-related biomarkers following daily oral administration in participants at risk for or at the prodromal stage of alzheimer’s disease.

a phase IIa, randomized, double-blind, placebo-controlled, multiple dose, multicenter, parallel-group study to investigate the safety, tolerability, and the effect of ro7269162 on amyloid and non-amyloid disease-related biomarkers following daily oral administration in participants at risk for or at the prodromal stage of alzheimer’s disease.

Datos básicos

Código:
BP44745
Protocolo:
BP44745
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2024
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

ROCHE FARMA, S.A.

Resultados del Ensayo Clínico

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.

Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose

Article. 10.3390/ijms25042112. 2024

  • Open Access.

Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1016/j.ejmp.2024.103345. 2024


Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.

Garcia-Lluch, Gemma; (...); Chafer-Pericas, Consuelo

Article. 10.1177/13872877241304995. 2024

  • Open Access.

Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024

  • Open Access.

Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Defining Alzheimer's Disease through Proteomic CSF Profiling.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1021/acs.jproteome.4c00590. 2024


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Endothelial Biomarkers Are Superior to Classic Inflammatory Biomarkers in Community-Acquired Pneumonia.

González-Jiménez P; (...); Méndez R

Article. 10.3390/biomedicines12102413. 2024

  • Open Access.

Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024


Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment.

Álvarez-Sánchez L; (...); Pericás CC

Article. 10.2174/011570159X332930240925095423. 2024


Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.

Baquero, Miguel; (...); Chafer-Pericas, Consuelo

Article. 10.3390/jcm13164735. 2024

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

New approach for early and specific Alzheimer disease diagnosis from different plasma biomarkers.

Forte, Anabel; (...); Chafer-Pericas, Consuelo

Article. 10.1016/j.cca.2024.117842. 2024


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024


Relationship between Plasma Lipid Profile and Cognitive Status in Early Alzheimer Disease.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms25105317. 2024

  • Open Access.

Campos de estudio

Compartir